EVGN

Evogene (NASDAQ) lands at 29 on the CIN composite, a Underweight outcome with conviction of 1/5. Fundamentals carry 35 percent of the model, regulatory posture 25, market signal 25, and editorial density 15, with every pillar contribution auditable. Regulatory leads the pillar table at 55, and is the main lever behind the Underweight conclusion. The offset comes from fundamentals at 2, which pulls the composite toward the middle of the band.

The observable inputs tell a straightforward story: reported revenue growth of -86.3 percent year over year, an operating margin of -952.1 percent, a market cap near 6 million. Every figure is auditable in the accompanying pillar table. All inputs are drawn from primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage density. Because every ticker in the CIN universe is scored on the same 336-name basis, Evogene (NASDAQ) slots into a direct comparison rather than a bespoke narrative, and the score refreshes on the primary-source ingest cadence.

Regulatory posture is where the rating breathes. That pillar contributes 55, and a step-up in filing frequency without any enforcement activity would be the cleanest catalyst for a tighter reading.